Cetoxim, also known as cefixime, is a potent antibiotic belonging to the cephalosporin class of
beta-lactam antibiotics. It is widely used in the treatment of various bacterial infections due to its broad spectrum of activity and favorable safety profile.
Cetoxim is a third-generation cephalosporin antibiotic that exhibits a wide range of antibacterial activity against both gram-positive and gram-negative bacteria. It is highly effective in treating various types of
infections, including respiratory tract
infections, urinary tract
infections, and gonorrhea.
Cetoxim works by inhibiting bacterial cell wall synthesis, ultimately leading to the death of the targeted bacteria.
Cetoxim has the chemical formula C16H15N5O7S2 and the CID (Compound Identifier) 5362065. Its molecular structure consists of a cephem nucleus and a diazabicyclooctane ring, which contribute to its potent antibacterial activity.
The PubChem website provides detailed information about the chemical structure and properties of Cetoxim.
Cetoxim exerts its antibacterial effects by inhibiting the synthesis of bacterial cell walls. Specifically, it binds to and inactivates penicillin-binding proteins (PBPs), which are essential enzymes involved in the formation of the peptidoglycan layer of the bacterial cell wall. By disrupting this crucial step,
Cetoxim prevents the proper formation of the cell wall, leading to cell lysis and death of the bacteria.
Cetoxim is widely used in the treatment of various bacterial
infections, including: Due to its broad spectrum of activity,
Cetoxim is often used as a first-line antibiotic therapy for various
infections caused by susceptible bacteria.
Cetoxim is available in different forms and formulations, including: The availability and formulations may vary depending on the region and manufacturer. The recommended dosage of
Cetoxim varies based on the type and severity of the
infection, as well as the patient’s age and weight. For adults, the typical dosage ranges from 200mg to 400mg once daily, depending on the
infection being treated. For children, the dosage is adjusted based on body weight. It is essential to follow the prescribed dosage and duration of treatment to ensure optimal efficacy and minimize the risk of antibiotic resistance. While generally well-tolerated,
Cetoxim may cause some side effects, including: Severe side effects, such as anaphylactic reactions, are rare but can occur in some individuals.
Cetoxim should be used with caution in patients with known allergies to cephalosporin antibiotics or those with impaired renal function.
Cetoxim is well-absorbed after oral administration, with a bioavailability of around 40-50%. It is widely distributed throughout the body and can penetrate various tissues and fluids, including the cerebrospinal fluid.
Cetoxim is primarily excreted through the kidneys, with a half-life of approximately 3-4 hours in individuals with normal renal function. The pharmacodynamic properties of
Cetoxim are characterized by its time-dependent killing of bacteria, meaning that its efficacy is primarily determined by the duration of exposure rather than the peak concentration. While
Cetoxim is generally effective against a wide range of bacteria, resistance can develop due to various mechanisms, such as the production of extended-spectrum beta-lactamases (ESBLs) or alterations in the target penicillin-binding proteins.
Studies have reported varying levels of resistance among different bacterial species, highlighting the importance of monitoring resistance patterns and implementing appropriate antibiotic stewardship practices.
Cetoxim is available under various brand names, including Ceroxim, manufactured by SUN PHARMACEUTICALS MOROCCO LLC. The availability and pricing of
Cetoxim may vary depending on the region and local market conditions.
Cetoxim has been the subject of numerous research studies and clinical trials, exploring its efficacy, safety, and potential applications in various infectious diseases. Ongoing research efforts aim to optimize dosing regimens, explore novel formulations, and investigate potential synergistic effects with other antimicrobial agents. Patients prescribed
Cetoxim should carefully follow the instructions provided by their healthcare provider, including the dosage, duration of treatment, and any precautions or warnings. It is important to complete the full course of treatment to prevent the development of antibiotic resistance and ensure complete eradication of the
infection.
Cetoxim should be stored at the recommended temperature and protected from light and moisture to maintain its potency and stability. The specific storage conditions may vary depending on the formulation and manufacturer’s instructions.
Cetoxim has been approved for use by various health authorities worldwide, including the U.S. Food and Drug Administration (FDA) and the European
Medicines Agency (EMA). However, its prescription status and legal regulations may vary across different countries.
Cetoxim shares several similarities with other beta-lactam antibiotics, such as ceftriaxone and cefotaxime, in terms of its mechanism of action and spectrum of activity. However, it may differ in terms of its pharmacokinetic properties, dosing regimens, and specific indications. Comparative studies have been conducted to evaluate the relative efficacy and safety of
Cetoxim against other antibiotics in various clinical scenarios.
Cetoxim is widely available and used globally for the treatment of various bacterial
infections. However, access to this antibiotic may be limited in certain regions due to factors such as cost, availability, and healthcare infrastructure. Efforts are ongoing to improve access to essential antibiotics, including Cetoxim, in underserved areas to address global health challenges. Numerous case studies and clinical practice reports have documented the successful use of
Cetoxim in treating a variety of
infections, including respiratory tract
infections, urinary tract
infections, and gonorrhea. These real-world applications and practitioner endorsements further support the efficacy and utility of
Cetoxim in clinical practice.
Cetoxim was developed in the 1970s as a part of the cephalosporin class of antibiotics. Its discovery and subsequent introduction into medical practice marked a significant advancement in the treatment of bacterial
infections, particularly those caused by resistant strains. Numerous
in vitro and
in vivo studies have been conducted to evaluate the antibacterial activity, pharmacokinetics, and safety profile of Cetoxim. These studies have provided valuable insights into the drug’s mechanisms of action, potential resistance mechanisms, and optimal dosing regimens. For further information and resources related to Cetoxim, please refer to the following:Cetoxim | Uses, Benefits, Side Effects, Dosage
Table of Contents
Introduction to Cetoxim
Chemical Composition and Structure
Mechanism of Action
Therapeutic Uses
Forms and Formulations
Administration and Dosage
Side Effects and Precautions
Pharmacokinetics and Pharmacodynamics
Resistance and Efficacy
Commercial Information
Research and Development
Patient Information
Storage and Handling
Regulatory Status
Comparison with Other
Antibiotics
Global Use and Accessibility
Case Studies and Clinical Practice
Historical Development
In Vitro and In Vivo Studies
Additional Resources
